Evidence map›Paper›PMID 30026756›Full record

ArticleBioinorganic chemistry and applications2018

Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(

Samuel Treviño, Alfonso Díaz, Eduardo Sánchez-Lara, Víctor Enrique Sarmiento-Ortega, José Ángel Flores-Hernández, Eduardo Brambila, Francisco J Meléndez, Enrique González-Vergara

Open access · goldAbstract read
In one paragraph

Article in Bioinorganic chemistry and applications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Tris(2-Pyridylmethylamine)V(O)Frontiers in chemistry · 2022
    Article
  6. Article
  7. Sodium metavanadate treatment improves glycogen levels in multiple tissues in a model of metabolic syndrome caused by chronic cadmium exposure in Wistar rats.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Samuel TreviñoFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, 72570 Puebla, PUE, Mexico.
Alfonso DíazFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, 72570 Puebla, PUE, Mexico.
Eduardo Sánchez-LaraCentro de Química, ICUAP, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, 72570 Puebla, PUE, Mexico.
Víctor Enrique Sarmiento-OrtegaFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, 72570 Puebla, PUE, Mexico.
José Ángel Flores-HernándezFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, 72570 Puebla, PUE, Mexico.
Eduardo BrambilaFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, 72570 Puebla, PUE, Mexico.ORCID 0000-0003-0377-0943
Francisco J MeléndezFacultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, 72570 Puebla, PUE, Mexico.
Enrique González-VergaraCentro de Química, ICUAP, Benemérita Universidad Autónoma de Puebla, 14 Sur y Av. San Claudio, Col. San Manuel, 72570 Puebla, PUE, Mexico.ORCID 0000-0002-9883-4921
Benemérita Universidad Autónoma de Puebla · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vanadium(IV/V) compounds have been studied as possible metallopharmaceutical drugs against diabetes mellitus. However, mechanisms of action and toxicological threshold have been tackled poorly so far. In this paper, our purposes were to evaluate the metabolic activity on dyslipidemia and dysglycemia, insulin signaling in liver and adipose tissue, and toxicology of the title compound. To do so, the previously reported bisammonium tetrakis 4-(

Identifiers

PMID30026756
PMCPMC6031092
OpenAlexW2809343046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.